Pear Therapeutics snaps up depression-focused DTx assets

Pear Therapeutics seeks to enter the despair area with the acquisition of the assets of digital remedy firm Waypoint Health Innovations, in addition to the assets of rebro University researcher Fredrik Hollndare.

Adding these despair assets to our portfolio matches completely with our quick time period objective of increasing our management in psychiatry. With these agreements, we have now the potential to optimize our PDT candidate for despair to assist deal with one of many largest psychological and behavioral well being affected person populations, stated Corey McCann, President and CEO of Pear Therapeutics. .

Waypoints DTx makes use of cognitive behavioral remedy strategies to assist deal with despair. Its remedy is delivered via symptom assessments, movies, interactive instruments and personalised algorithms. DTx has been the topic of a number of scientific research, however the firm has but to submit its work to the FDA.

Hollndare created an Internet-based CBT (iCBT) centered on residual signs of despair and the combat towards relapses. The iCBT is split into 9 totally different modules, together with these on Behavioral Activation, Cognitive Restructuring, Sleep, Relaxation, Mindfulness, and different areas.


Depression is a typical situation within the United States. In truth, 4.7% of all adults over 18 frequently expertise emotions of despair, According to the CDC.

During the COVID-19 pandemic, charges of tension and despair have risen sharply. According toKaiser Family Foundation Research, in January 2021, 41.1% of adults had signs of tension or depressive dysfunction.


Earlier this month, Pear accomplished his Merged SPAC and began buying and selling on the Nasdaq. The firm made headlines when it acquired a De Novo from the FDA in 2017 for its digital remedy known as reSET, which centered on drug habit remedy. He has since obtained FDA 510 (okay) clearance for his remedy of opioid use issues and his insomnia-focused DTx.

The firm has a variety of different remedies within the works. For instance, he is additionally engaged on a DTx for schizophrenia. When the FDA eased restrictions on digital psychological well being instruments in the course of the COVID-19 pandemic, Pear launched it for restricted distribution in April 2020.

Pear is not the one digital remedy firm trying to assist deal with despair.Happify Health rolled out its first PDTx for nervousness and despair over the summer season. However, Happify Health nonetheless doesn’t have FDA clearance and can also be benefiting from relaxed FDA laws.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button